Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETIC-LM Phase II Tucatinib + Capecitabine + Intra-CSF Trastuzumab in HER2-positive Breast Cancer with Leptomeningeal Metastases
2022-502351-60-00Phase 2Authorised
- Sponsor
- Unicancer
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucatinib, capecitabine and trastuzumab in breast cancer, Carcinomatous Meningitis (CM) and brain metastases, sponsored by Unicancer. Primary endpoint: 12-month overall survival rate. Planned start Sep 2023; status: authorised.
02
Drugs
03
Conditions
breast cancerCarcinomatous Meningitis (CM)brain metastases
Beyond the preview
Go deeper on 2022-502351-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502351-60-00.